Garrett Mary
Known title: DirectorCIK: 0001663588
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Omnicell Set to Release Q3 2026 Results; Guidance Update. Omnicell will publish its third‑quarter 2026 earnings on Oct. 29, 2026. Analysts noted the company beat revenue expectations but issued weaker EBITDA guidance, which may affect the bullish outlook. The stock is currently near its 12‑touch support level of $42.89 and trades below the average analyst target of $57.86.
Transaction History
| PRCT | ▲ Buy | Grant | 3,315 | $0 | 6/9/2026 | View on chart |
| OMCL | ▲ Buy | Grant | 5,027 | $0 | 6/1/2026 | View on chart |
| PRCT | ▲ Buy | Grant | 1,538 | $0 | 6/10/2025 | View on chart |
| OMCL | ▲ Buy | Grant | 7,084 | $0 | 6/1/2025 | View on chart |
| PRCT | ▲ Buy | Grant | 1,376 | $0 | 6/4/2024 | View on chart |
| OMCL | ▲ Buy | Grant | 6,058 | $0 | 5/21/2024 | View on chart |
| PRCT | ▲ Buy | Grant | 2,711 | $0 | 6/15/2023 | View on chart |
| OMCL | ▲ Buy | Grant | 2,522 | $0 | 5/23/2023 | View on chart |
| PRCT | ▲ Buy | Grant | 2,001 | $75K | 6/7/2022 | View on chart |
| OMCL | ▲ Buy | Grant | 1,511 | $0 | 5/24/2022 | View on chart |
| PRCT | ▲ Buy | Grant | 6,759 | $200K | 12/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
THINK Surgical Names Rick McDowell VP of Sales
THINK Surgical, a subsidiary of PROCEPT BioRobotics, has appointed Rick McDowell as Vice President of Sales. This leadership addition is intended to support the company's commercial operations. The stock is currently trading near its 52-week low, with an average analyst target of $21.64.
THINK Surgical Names Rick McDowell VP of Sales. THINK Surgical, a subsidiary of PROCEPT BioRobotics, has appointed Rick McDowell as Vice President of Sales. This leadership addition is intended to support the company's commercial operations. The stock is currently trading near its 52-week low, with an average analyst target of $21.64.